FDA Expands Marstacimab Indication in Hemophilia A and B - Top-Institutions - MDSpire

FDA Expands Marstacimab Indication in Hemophilia A and B

  • By

  • Kathryn Wighton

  • June 8, 2026

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    McMaster University/Hamilton Health Sciences
    McMaster University/Hamilton Health Sciences

    Hamilton, Ontario

    Key Differentiators

    • Hematology
    • Thrombosis

  • #2

    Northwell Health Hemostasis & Thrombosis Center
    Northwell Health Hemostasis & Thrombosis Center

    New Hyde Park, New York

    Key Differentiators

    • Hematology
    • Thrombosis

Original Source(s)

FDA Expands Marstacimab Indication in Hemophilia A and B

  • by Kathryn Wighton

  • June 8, 2026

Related Content

Exploring Vaping Cessation App Use Among Youth: Qualitative Descriptive Study

Prevalence of undernutrition at admission and associated factors among children with cancer admitted to the University Hospital of Tangier: a cross-sectional study

FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure

Phase 3 data showed a 67% reduction in symptomatic infection among exposed household contacts who tested negative at baseline.